The immune checkpoint inhibitors (ICIs) blocking programmed cell death 1 (PD-1) represent an unprecedented breakthrough in the treatment of advanced non-small cell lung cancer (NSCLC) (1). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.